Conference Day One - Wednesday November 5, 2025

Download the Full Event Guide to explore detailed information about all sessions, speakers, and activities!

Full Event Guide

8:00 am Check-In & Light Breakfast

8:55 am Chair’s Opening Remarks

Contextualizing Inflammasome-Related Disease Pathogenesis to Unveil Clinical Milestones

9:00 am Targeting NLRP3 in Myelodysplastic Syndrome: Initial Results from Phase Ib Trial of DFV890

9:30 am Preclinical & Clinical Evaluation of the Brain Penetrant NLRP3 Inhibitor, NT-0796 in Obesity & Cardiometabolic Disease

  • Alan Watt President & Chief Scientific Officer, NodThera Ltd.

10:00 am Speaking Position Reserved for Alamar Biosciences

10:30 am Morning Refreshments & Speed Networking

Harnessing Mechanism-Based Biomarkers to Translate Inflammasome Activity into Clinical Efficacy

11:30 am NLRP3-Mediated Inflammation: Novel Strategy for Neurodegenerative & Cardiometabolic Disease Intervention

  • John Nuss Chief Scientific Officer, Ventyx Biosciences
  • Kathleen Ogilvie Senior Vice President - Translational & Non-Clinical Research, Ventyx Biosciences

12:00 pm A New Predictive Frontier: Cellular-Level Inflammasome Biomarkers in Traumatic Brain Injury

12:30 pm Lunch & Networking

Cracking the Molecular Mechanisms to Reframe Inflammasome Research on Novel Targets

1:30 pm Targeting Innate Immunity: Inflammasomes & Myeloid Cells in Chronic Inflammation & Tissue Repair

2:00 pm A Mechanistic Deep Dive: Tackling the Molecular Interplay with Caspases, Apoptosis & Pyroptosis

  • Olaf Groß Professor, Principal Investigator, University Medical Center Freiburg

2:30 pm Afternoon Refreshments & Poster Session

Building a Future-Proof Indication Strategy to Achieve Long-Term Clinical Success

3:30 pm Strategic Prioritization of Inflammatory Indications: Navigating Risk, Reward & Clinical Feasibility

4:00 pm Fireside Chat: What Each Stakeholder Needs – Repositioning Inflammasome Therapies for Clinical, Commercial & Capital Success

  • Elliott Gruskin Chief Executive Officer, Azome Therapeutics
  • Paul Ashton President & Chief Executive Officer, Inflammasome Therapeutics

4:45 pm End of Conference Day One

5:00 pm Chair’s Closing Remarks

Full Event Guide
Pre-Conference Workshop Day
Day Two